Reprogramming adoptive cell therapy for osteosarcoma: engineering, vaccination, and tumor microenvironment...

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Osteosarcoma presents significant treatment challenges, particularly in recurrent, refractory, or metastatic cases.
• Adoptive cell therapy (ACT) offers a promising strategy, but faces hurdles like antigen heterogeneity, toxicity, and immunosuppression.

Purpose of the Study:

• To review emerging innovations in ACT for osteosarcoma.
• To discuss strategies for overcoming safety and efficacy barriers in osteosarcoma treatment.

Main Methods:

• Engineering strategies: multi-antigen recognition, logic-gated systems, suicide switches, transient expression, cytokine circuits, checkpoint resistance, chemokine modification.
• Vaccination approaches: enhancing in vivo expansion, immune memory, antigen spreading, and local inflammation.
• Tumor microenvironment remodeling: stromal modulation, vascular normalization, myeloid reprogramming, checkpoint blockade, metabolic intervention.

Main Results:

• Engineered T cells and NK cells can be designed for improved precision, control, and durability.
• Vaccines can amplify ACT efficacy by promoting expansion and immune memory.
• Modifying the tumor microenvironment can create a more receptive niche for cellular therapies.

Conclusions:

• Next-generation ACT for osteosarcoma requires integrated approaches combining cellular engineering, vaccine boosting, and microenvironment remodeling.
• Modular, biomarker-guided combinations are key for safer and more durable antitumor responses in osteosarcoma.